



Survey Based Analysis of T1DM Patient Training Experience with Omnipod 5 Pump

Kaveri Bhargava, BA¹, Marina Basina, MD²

¹Stanford University School of Medicine COMET Fellowship; ²Stanford Medicine Division of Endocrinology, Gerontology, and Metabolism




Background

The Omnipod 5 pump system (OP5) was approved by the FDA in 2022 for patients with Type I Diabetes Mellitus for ages 2 and above. The OP5 User Guide provides detailed instructions for self training (ST) of patients and caregivers, and patients can also opt to receive formal training (FT) by Certified Pump Trainers. Despite these measures, there is limited data available regarding best pump training practices and their effectiveness from the patient's perspective. We conducted a patient survey to evaluate educational needs, training satisfaction, and need for additional pump training sessions.


Aim Statement

For adult patients (>18 years) using OP5 a) assess patient satisfaction with ST/FT to establish baseline and b) increase the proportion who report initial training as "Sufficient/ Somewhat Sufficient" by 20% by implementing a follow-up training process by August 2025.

Fishbone Diagram



Key Driver Diagram




Results

		Formally Trained (FT)	Self-Trained (ST)	P- value
Diabetes Regimen Prior to Starting OP5	Multiple Daily Injections (MDI)	16/27 (59%)	2/14 (14%)	NS* (p = 0.17)
	Insulin Pump	10/27 (37%)	12/14 (86%)	
	Other	1/27 (4%)	0/14 (0%)	
Duration of OP5 Use	≤ 6 months	4/27 (15%)	3/14 (21%)	NS* (p = 0.14)
	>6 months	23/27 (85%)	11/14 (79%)	
Sufficiency of Training	Sufficient	22/27 (81%)	8/14 (57%)	NS* (p= 0.41)
	Neutral	1/27 (4%)	1/14 (7%)	
	Not Sufficient	4/27 (15%)	5/14 (36%)	
Favorable Impressions of OP5 Within First 1-3 Months of Use	Favorable	22/27 (81%)	12/14 (86%)	NS* (p= 0.10)
	Neutral	1/27 (4%)	1/14 (7%)	
	Somewhat Unfavorable	4/27 (15%)	1/14 (7%)	
Frequency of Low Blood Sugars Since Starting OP5	Increased	0/27 (0%)	3/14 (21%)	NS* (p = 0.45)
	Decreased	19/27 (70%)	6/14 (43%)	
	Stayed the same	8/27 (30%)	5/14 (36%)	
Additional Trainings Preferred	None	14/27 (52%)	9/14 (64%)	NS* (p = 0.13)
	1-2 Sessions	11/27 (41%)	4/14 (29%)	
	2-4 Sessions	2/27 (7%)	1/14 (7%)	

*NS denotes Not Significant

Implementation



Conclusion

Insulin pumps are empowering self-management tools for diabetes patients and effective device training is of paramount importance. Rapidly expanding use of diabetes technology significantly impacts patients' lives. However, with increasing healthcare costs, there is an urgent need for low-cost and effective patient education strategies for these devices.

Patients' satisfaction with ST or FT has not been previously evaluated for OP5. Our survey demonstrated similar patients' satisfaction with ST and FT methods. Patient's understanding of the pump's functionality affects satisfaction.

Considering the individual variability in learning and assimilation, availability of online materials, allocation of resources, and time, ST can be a viable option for some patients with additional follow up or ongoing training sessions. Post-test assessment of patient knowledge showed advanced understanding of OP5. Larger and longer studies are needed.